Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on AdAlta.
RELATED STOCKHEAD STORIES
Stockhead TV
Long Shortz with AdAlta: Progressive partnership to spread life-saving immunotherapies
Health & Biotech
AdAlta secures Cell Therapies as cellular immunotherapies manufacturer
News
Closing Bell: Oil weighs on flat ASX; Errawarra jumps 65pc on scent of fresh lithium
Health & Biotech
ASX Health Stocks: Optiscan jumps after signing robotic surgery deal with Mayo Clinic
News
Market Highlights: Novovax doubles; Chalmers calls critical minerals a ‘golden opportunity’
Health & Biotech
AdAlta locks in $3.7m to speed up Phase II clinical trials, near-term partnerships
Stockhead TV
Long Shortz with AdAlta: Strengthening bonds in the fight against cancer
Health & Biotech
AdAlta and SYNthesis BioVentures collaborate on advanced cell-based cancer immunotherapy
Health & Biotech
‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 1
News
ASX Small Caps and IPO Weekly Wrap: Gold and medicine are the best medicine
Health & Biotech
ScoPo’s (actually Wilkie’s) Powerplays: Health stocks rise as AdAlta soars 17% on trial results
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Cettire rejects AFR claims, GDP’s gone back to the 90’s and ASX200 ends above the ice
Health & Biotech
AdAlta’s Ad-214 extension study reaches milestone for Phase II clinical studies and partnering
News
ASX Small Caps Lunch Wrap: GDP drama is over, now markets brace for the lack of drama, drama
Health & Biotech
ASX Health Stocks: Atomo pops 90pc after purchase order; AdAlta up 20pc on Phase 1 results
News
